Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTUDR0C)

• DTT Name: Iron (Fe)
• Gene Name: Fe
• DTT Type: Successful target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T02246

Molecular Interaction Atlas (MIA) of This DTT

4 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deferiprone	DMS2M7O	Beta thalassemia	3A50.2	Approved	[1]
Deferoxamine Mesylate	DMTUKZH	Acute iron or aluminum toxicity	FB83.20	Approved	[2]
Etidronate Disodium	DMAWJIN	Osteoporosis	FB83.0	Approved	[2]
Exjade	DMHPRWG	Iron overload disease	5C64.10	Approved	[3]

4 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Soluble ferric pyrophosphate	DMLAYTP	Iron-deficiency anemia	3A00	Phase 3	[4]
SPD602	DMKJ9LU	Anemia	3A00-3A9Z	Phase 2	[5]
DpC	DM4ZDOE	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
Monohydroxyethylrutoside	DMAQJHO	Cardiovascular disease	BA00-BE2Z	Phase 1	[7]

References

• [1] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30.
• [4] A micronised, dispersible ferric pyrophosphate with high relative bioavailability in man. Br J Nutr. 2004 Jan;91(1):107-12.
• [5] ClinicalTrials.gov (NCT01604941) Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy. U.S. National Institutes of Health.
• [6] Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxid Redox Signal. 2019 Mar 10;30(8):1062-1082.
• [7] Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res. 1997 Oct;3(10):1747-54.